

1 **Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-**
2 **1237 mRNA vaccine by commercial antibody tests**

3
4 Running title: Detection of mRNA vaccine induced SARS-CoV-2 IgG antibodies

5
6 Jamil N Kanji, MD, DTMH&H, FRCP(C)^{a-c,*}, # Ashley Bailey, MLS^b, Jayne Fenton, MLT^b
7 Sean H Ling, MB, BCh, BAO, MSc^b, Rafael Rivera^d, Sabrina Plitt, PhD^{d,e}, Wendy I Sligl,
8 MD, MSc, FRCP(C)^{a,f}, Sean Taylor, PhD^g, LeeAnn Turnbull, MLT^b, Graham Tipples, PhD,
9 FCCM, D(ABMM)^{b,h,i}, Carmen L. Charlton, PhD, FCCM, D(ABMM)^{b,c,h}

10
11 Affiliations:

- 12
13 a. Division of Infectious Diseases, Department of Medicine, University of Alberta, 8440
14 – 112 Street NW, Edmonton, AB, T6G 2B7, Canada
15 b. Public Health Laboratory, Alberta Precision Laboratories, University of Alberta
16 Hospital, University of Alberta Hospital, 8440 – 112 Street NW, Edmonton, AB T6G
17 2B7, Canada
18 c. Department of Laboratory Medicine & Pathology, Faculty of Medicine and Dentistry,
19 University of Alberta Hospital, 8440 – 112 Street NW, Edmonton, AB, T6G 2B7,
20 Canada
21 d. School of Public Health, University of Alberta, 3-003 Edmonton Clinic Health
22 Academy, 11405-87 Avenue NW, Edmonton, AB, T6G 1C9, Canada
23 e. Centre for Communicable Diseases and Infection Control, Public Health Agency of
24 Canada, Ottawa, ON, K1A 0K9, Canada
25 f. Department of Critical Care Medicine, University of Alberta, 8440 – 112 Street NW,
26 Edmonton, AB T6G 2B7, Canada
27 g. GenScript USA Inc, 860 Centennial Avenue, Piscataway, NJ 08854, USA
28 h. Li Ka Shing Institute of Virology, University of Alberta, 6-010 Katz Group Centre for
29 Pharmacy and Health Research, Edmonton, AB, T6G 2E1, Canada
30 i. Department of Medical Microbiology and Immunology, Faculty of Medicine and
31 Dentistry, University of Alberta, 8440 – 112 Street NW, Edmonton, AB, T6G 2B7,
32 Canada

33
34 Word count:

35 Abstract – 250

36 Manuscript (excluding methods, tables/graphics/references): 2496

37
38 #Corresponding author:

39 Jamil N. Kanji, MD, DTM&H, FRCP(C)
40 Public Health Laboratory, Alberta Precision Laboratories
41 Foothills Medical Centre
42 3030 Hospital Drive NW, Calgary, AB, T2N 4W4
43 Phone: +1 403 944 1200; Fax: +1 403 270 2216
44 Email: jamil.kanji@ahs.ca

45
46 *Dr. Jamil N. Kanji is now with the Division of Infectious Diseases, Department of
47 Medicine, University of Calgary and with the Public Health Laboratory (Alberta Precision
48 Laboratories) at the Foothills Medical Centre, 3030 Hospital Drive NW, Calgary, AB, T2N
49 4W4, Canada.

50 **ABSTRACT**

51 **PURPOSE**

52 With rapid approval of SARS-CoV-2 vaccines, the ability of clinical laboratories to detect
53 vaccine-induced antibodies with available high-throughput commercial assays is unknown.

54 We aimed to determine if commercial serology assays can detect vaccine-induced antibodies
55 (VIAs) and understand the vaccination response.

56 **METHODS**

57 This cohort study recruited healthcare workers and residents of long-term care facilities
58 (receiving the BNT162b2 and mRNA-1273 products, respectively) who underwent serum
59 collection pre-vaccination (BNT162b2 group), 2-weeks post vaccination (both groups), and
60 pre-2nd dose (both groups). Sera were tested for the presence of SARS-CoV-2 IgG using four
61 commercial assays (Abbott Architect SARS-CoV-2 IgG, Abbott Architect SARS-CoV-2 IgG
62 II Quant, DiaSorin Liaison Trimeric S IgG, and GenScript cPASS) to detect VIAs.

63 Secondary outcomes included description of post-vaccination antibody response and
64 correlation with neutralising titers.

65 **RESULTS**

66 225 participants (177 receiving BNT162b2 and 48 receiving mRNA-1273) were included
67 (median age 41 years,; 66-78% female). Nucleocapsid IgG was found in 4.1% and 21.9% of
68 the BNT162b2 (baseline) and mRNA-1273 (2-weeks post first dose). All anti-spike assays
69 detected antibodies post-vaccination, with an average increase of 87.2% (range 73.8-94.3%;
70 BNT162b2), and 25.2% (range 23.8-26.7%; mRNA-1273) between the first and last sampling
71 time points (all $p < 0.05$). Neutralising antibodies were detected at all post-vaccine timepoints
72 for both vaccine arms, with increasing titers over time (all $p < 0.05$).

73 CONCLUSION

74 Anti-spike vaccine-induced SARS-CoV-2 IgG are detectable by commercially available
75 high-throughput assays and increases over time. Prior to second dose of vaccination,
76 neutralising antibodies are detectable in 73-89% of individuals, suggesting the majority of
77 individuals would have some degree of protection from subsequent infection.

78

79 Key words:

80 SARS-CoV-2, neutralising antibodies, commercial assays, mRNA vaccine, mRNA-1273,
81 BNT162b2, spike protein, receptor binding domain, trimeric

82 **Introduction**

83 To date, the principal utility of SARS-CoV-2 IgG high throughput serology assays has been
84 to conduct seroprevalence studies for large cohorts to aid public health decision-making [1,
85 2]. Until recently, all seroprevalence studies have examined detection of antibodies from
86 natural infection. While most vaccine candidates produced detectable antibody levels on
87 specific serological research assays in early phase trials [3-5], it is unclear how currently
88 available high-throughput commercial assays will detect vaccine-induced antibody in the
89 clinical laboratory. In the case of varicella, detection of vaccine-induced antibody is variable
90 among commercial kits compared to detection of antibodies produced from natural infection,
91 which are more robust [6].

92

93 SARS-CoV-2 neutralization antibodies have been shown to predict disease severity and
94 survival [7]. There is also evidence of their protective capacity in preventing infection in
95 animal models and humans [8-10]. These data corroborate evidence for neutralising antibody
96 (nAb) protection in numerous viral infections including yellow fever, encephalitis, dengue,
97 mumps, influenza and others [11]. To date, there is little data measuring the level of nAbs
98 pre/post-vaccination for SARS-CoV-2 nor how results compare with vaccine efficacy and
99 protection.

100

101 Currently approved SARS-CoV-2 vaccines in the United States and Canada (BNT162b2 and
102 mRNA-1273 products) consist of lipid nanoparticles formulated nucleoside-modified
103 messenger RNA (mRNA) [12, 13]. Both formulations induce T-cell activation and
104 production of antibodies in response to *in vivo* production of SARS-CoV-2 spike (S) protein
105 following translation of the synthetic mRNA in human cells [14]. Antibodies against the

106 receptor binding domain (RBD) found in the S1 region of the spike gene [3, 15], anti-S1
107 protein IgG [14], as well as neutralising antibody [14, 16] have been detected in response to
108 both vaccines.

109

110 We aimed to evaluate the ability of three commercial SARS-CoV-2 IgG assays and one
111 functional nAb test to detect and quantify antibodies in two separate patient populations
112 receiving their first doses of the BNT162b2 and mRNA-1273 SARS-CoV-2 mRNA vaccines.
113 It was hypothesized that assays targeting non-spike proteins (e.g., nucleocapsid (N) protein)
114 would screen positive only in individuals who previously recovered from natural SARS-
115 CoV-2 infection. It was further postulated that there could be a difference between the IgG
116 binding antibody total immune response versus the nAb response to vaccination.

117

118 **Methods**

119 *Participant sample collection*

120 Serum samples were collected prospectively from two separate patient groups undergoing
121 COVID-19 vaccination. The first group consisted of healthcare workers (HCWs) who
122 received the BNT162b2 vaccine series while the second group consisted of residents of long-
123 term care facilities who received the mRNA-1273 vaccine series. Herein the groups will be
124 referred to as the BNT162b2 and the mRNA-1273 groups, respectively.

125

126 Serum samples in the BNT162b2 group were planned to be drawn at the following
127 approximate time points: (i) at baseline (defined as 24-72 hours prior to the first dose, or up
128 to five days post the first dose of vaccine), (ii) 14 days post first dose of vaccine; and (iii)

129 within 24 hours of the second dose of vaccine (either the day before, day of, or day prior).
130 Those in the mRNA-1273 group were planned to have samples collected at approximately (i)
131 14 days and (ii) 21-28 days post first dose of vaccine (pre-2nd dose). Due to the rapid roll out
132 of vaccine in long-term care facilities, none of the participants in the mRNA-1273 group had
133 baseline/pre-first dose samples collected.

134

135 *Vaccine distribution*

136 Details regarding Alberta COVID-19 vaccine distribution have been outlined previously [17].
137 Briefly, given the need for storage at -70°C, the BNT162b2 vaccine was provided to
138 healthcare workers (those working in areas of intensive care, emergency, care of COVID-19
139 positive patients, and those working in long-term care) at a centralized vaccine depot. The
140 mRNA-1273 product was transported for administration to residents of continuing and long-
141 term care facilities (given ability to store at -20°C) [17]. The two doses of the BNT162b2 and
142 mRNA-1273 products were administered three and four weeks apart, respectively as per
143 vaccine manufacturer recommendations.

144

145 Vaccine administration and allocation was directed as per planned vaccine roll-out by
146 provincial government health authorities and not by the researchers. Inclusion criteria to
147 participate this study comprised being 18 years or older, eligible for and planned COVID-19
148 vaccine series. Participants who had recovered from previous SARS-CoV-2 infection, who
149 were on biologics or other immunosuppressive medications, or who were pregnant were
150 included.

151

152 *SARS-CoV-2 IgG detection*

153 Samples were stored at -20°C and underwent one freeze-thaw cycle prior to testing. Sera
154 were tested for SARS-CoV-2 IgG using three high-throughput commercial assays: Abbott
155 Architect SARS-CoV-2 IgG (IgG targeting the N-protein; qualitative result only) [18],
156 Abbott Architect SARS-CoV-2 IgG II Quant (IgG targeting the RBD-region of the S-protein;
157 quantitative result) [18], and DiaSorin Liaison (trimeric S-protein assay targeting the S1/S2
158 regions of the S-protein; quantitative result) [19]. In addition, we evaluated the presence of
159 SARS-CoV-2 nAbs using the GenScript cPass Neutralisation antibody detection kit (Table
160 S1) [20, 21]. All testing was done according to product inserts and qualitative and
161 quantitative values (where available) were recorded for each assay. Only the assay by
162 GenScript has a claim to detect nAbs.

163

164 *Data analysis*

165 Baseline demographics of all participants were extracted from the provincial electronic
166 medical record (EMR) (Table S1). Continuous variables were compared using Mann-
167 Whitney tests while categorical variables were compared using Chi-square or Fisher's exact
168 tests. All statistical analysis and graphing were done using Stata version 16.1 (Table S1).

169

170

171 **Results**

172 *Population demographics*

173 Serum from 225 participants who received an mRNA COVID-19 vaccine (177 receiving the
174 BNT162b2 and 48 receiving mRNA-1273) (Table 1) was collected at up to three timepoints.

175 The median age of all the participants was 41 years (with the mRNA-1273 having a
176 significantly higher median age; 84 vs 37 years). The majority of participants in each group
177 were female (66.7-78.1%). The median time between receipt of vaccine dose 1 and dose 2
178 for both groups was 25-26 days. A significantly higher proportion of mRNA-1273
179 participants had recovered from confirmed SARS-CoV-2 infection (33.3 vs 3.4%). Two
180 participants in the BNT162b2 group were diagnosed with COVID-19 after receipt of their
181 vaccine (one diagnosed seven days after the first dose; the other nine days after the second
182 dose). Medical comorbidities were more commonly seen in the mRNA-1273 group. In total,
183 five participants were being treated with biologics or immunosuppressive medications.

184

185 *Anti-nucleocapsid IgG detection*

186 IgG directed towards the SARS-CoV-2 N-protein was found in 3.6-5.4% and 18.9-21.9% of
187 the BNT162b2 and mRNA-1273 groups, respectively (Fig. 1). Over the course of the blood
188 sampling times in each group, the positivity rate for anti-N IgG detection did not change
189 significantly from the baseline to pre-2nd dose sample ($p=0.86$; BNT162b2 group) and from
190 the 2-week and pre-2nd dose samples ($p=0.76$; mRNA-1273 group) in either group.

191 In the BNT162b2 group, all four participants who were COVID-19 recovered prior to their
192 first dose had a detectable anti-N IgG (Table S2). One of four lost their anti-N IgG when
193 tested two-weeks post first vaccine dose (60 days post diagnosis). 85.7% (6/7) COVID-19
194 recovered participants in the mRNA-1273 group had detectable anti-N IgG at 2-weeks post
195 first vaccine dose (Table S3) with no detectable anti-N IgG in 44.4% (4/9) participants just
196 prior to receiving their 2nd vaccine dose.

197

198 *Anti-Spike IgG and neutralising antibody detection and quantification*

199 The antibody positivity rate for all three S-protein based commercial assays (RBD IgG,
200 Trimeric S IgG, and GenScript nAb) increased on average by 87.2% (range 73.8-94.3%)
201 between baseline and the 2-week samples in the BNT162b2 group, reaching levels of >88%
202 positivity ($p < 0.0001$ for each assay) just prior to the second vaccine dose (Fig. 1). Similarly,
203 large positivity increases between 23.8 and 26.7% were observed between the 2-week post-
204 first dose and pre-2nd dose time points in the mRNA-1273 group with overall increases of
205 >50% and >70% positivity at the two time points respectively, $p < 0.05$ for all comparisons
206 (Table 2). For both time points and with both vaccines the number of participants who were
207 positive for nAbs was significantly lower than those who were positive for IgG binding
208 antibodies by a factor of 10% to 20% (Fig. 1).

209

210 Quantifiable titers of antibodies detected by each assay were detectable at all time points and
211 increased significantly over time in both vaccine groups (Table 2 and Fig. 2). In the
212 BNT162b2 group, titers increased by 1.8, 1.2, and 1.8-fold for the RBD IgG, Trimeric S IgG,
213 and GenScript nAb assays respectively, from the 2-week blood sampling to the samples
214 drawn just prior to the participants' 2nd dose (with a median number of 11 days between
215 blood draws). Higher-fold titer increases (3.5, 4.1, and 4.5-fold respectively) were seen in the
216 mRNA-1273 participants between blood sampling at similar time points ($p = 0.06$ for RBD
217 IgG and $p < 0.05$ for Trimeric S IgG and nAb assays) (median seven days between blood
218 draws) (Table 2 and Fig. 1). Titer values for a given group and time point were distributed
219 across varying IQRs despite being all classified as positive (Fig. S1).

220

221 *Post vaccine testing in special populations*

222 Quantitative titres in the mRNA-1273 group were found to be significantly higher among
223 participants who were COVID-19 recovered compared to those with no history of laboratory-
224 confirmed COVID-19 infection (Table S4; $p < 0.001$ for all assays at both time points). This
225 was observed for the two commercial anti-S IgG assays as well as the nAb assay used. This
226 comparison was made only in the mRNA-1273 group given all COVID-19 recovered
227 participants received their first dose of vaccine >14 days from the date of their COVID-19
228 diagnosis.

229

230 Our sample included a small number of participants ($n=5$; four from the BNT162b2 group)
231 on biologic or immunosuppressant therapy (Table S5). Four had no evidence of previous
232 COVID-19 infection at baseline. In the group of four (who all received the BNT162b2
233 vaccine), quantitative anti-S IgG/nAb were detected at 2-weeks (4/4) whereas only two
234 samples gave detectable levels of neutralising antibodies and the other two were close to
235 baseline. The absolute values of quantitative titres were comparatively larger for the one
236 participant who was COVID-19 recovered (mRNA-1273 group).

237

238 **Discussion**

239 In this study, we demonstrate that vaccine-induced antibodies stimulated by FDA approved
240 SARS-CoV-2 mRNA vaccines (BNT162b2 and mRNA-1273) can be detected by commercial
241 high-throughput assays currently used in clinical laboratories. As predicted, detectable
242 antibody was restricted to assays identifying IgG directed against the viral S-protein, and not
243 against the nucleocapsid protein. Anti-spike vaccine-induced antibodies were detectable as
244 early as ten days following the first dose of an mRNA vaccine. Titres increased significantly
245 over the three-week period from baseline sampling to pre-second dose sampling. Vaccine-

246 induced nAbs targeting the SARS-CoV-2 spike protein were successfully detected, using a
247 surrogate virus neutralization test (sVNT) kit without the use of cell lines and viral culture
248 required for plaque reduction neutralization assays (PRNT) supporting protective immunity
249 [7, 8, 10, 22]. However, there were significantly less participants with detectable nAbs post-
250 vaccination as those with a binding antibody IgG response.

251

252 To our knowledge, detection of vaccine-induced antibodies using commercial high-
253 throughput SARS-CoV-2 anti-S IgG assays has been limited to a partnership between
254 Roche® and Moderna® demonstrating detection of mRNA-1273 vaccine-induced antibodies
255 using the Elecsys anti-SARS-CoV-2 S test [15] two other studies [23, 24]. Our current study
256 adds to the literature by confirming the detection of these IgG binding and also functional
257 nAbs using commercial kits from other companies likely to be adopted by large volume
258 clinical laboratories.

259

260 Overall, our data demonstrate significant increases in the median titre of anti-S IgG by all
261 assays evaluated in both mRNA vaccine groups, except for the RBD IgG among the mRNA-
262 1273 group which did not measure levels from baseline but only from two weeks post
263 vaccination. Given the lack of an international standard, antibody titres can only be directly
264 compared between successive samples measured on the same assay run [25]. However, when
265 samples from participants in the same vaccine group on the same assay were compared, wide
266 IQRs of titre values were observed (Table 2; Fig. S1). The observed variation is likely
267 multifactorial, and dependant on history of previous SARS-CoV-2 infection, use of
268 immunosuppressive medications, advanced age, and frailty [26]. There is limited data to
269 conclude whether the differing titres in participants in the same group (classified qualitatively
270 as positive), assay, and time-point of sampling, translates to clinical differences in response to

271 infection. For other vaccines, such as hepatitis B and varicella, an initial antibody response
272 following first vaccine dose generally translates into protection from subsequent infection
273 [27, 28]. However, protection is derived from both humoral and cell-mediated responses, of
274 which only humoral is detected by the commercial high throughput EIAs [27, 28].

275

276 For other viral infections including SARS-CoV-2, there is significant evidence that nAbs are
277 correlated to protection and immunity [7, 11]. Animal challenge studies have provided
278 conclusive evidence for nAb protection to SARS-CoV-2 [22]. nAbs have also been
279 successfully tested in humans to treat the disease [29]. When comparing the prevalence of
280 neutralising and IgG antibodies from SARS-CoV-2 infected and recovered individuals, the
281 prevalence of nAbs was comparable to IgG binding antibodies and to gold standard PRNT
282 [30]. However, we found a significantly lower fraction of participants elicited protective
283 nAbs compared to those with IgG antibodies. A potential explanation is RBD IgG and
284 trimeric S IgG assays measure total binding antibodies, but are unable to differentiate
285 between nAbs and non-nAbs that also bind to the S-protein [31]. Several studies comparing
286 surrogate nAb assays to traditional methods (PRNT) have found them to be effective proxies
287 for detection and quantification of immunodominant nAbs seen in SARS-CoV-2 infection,
288 specifically RBD-targeting nAbs [21, 31] [32]. Encouragingly, at the final study blood draw
289 (pre-second vaccination dose), nAbs were detectable in 73-89% of samples tested from both
290 vaccine groups. Although the prevalence of nAbs remained significantly lower than total
291 binding IgG's, the data support that the majority of individuals would have at least some
292 protection from subsequent infection prior to the second dose, particularly as detection of
293 nAbs has been previously correlated with vaccine efficacy [33, 34]. However, these data
294 underline a cautionary note in that up to 27% of vaccinated individuals did not have

295 protective nAbs prior to the second dose and should remain vigilant in exercising protective
296 public health measures to limit viral spread.

297

298 In a post-COVID-19-vaccination era, it may not be necessary to differentiate between
299 vaccine induced antibody responses and natural infection. Although we found, at baseline, a
300 number of COVID-19 recovered participants had detectable anti-N IgG (which would
301 confirm previous infection), 30% were undetectable by the pre-second dose blood draw
302 (Table S2 and Table S3). This may be due to a number of factors including, the severity of
303 the initial SARS-CoV-2 infection [35], the specific anti-N IgG assay used [36], the natural
304 decline of N antibodies overtime [37], or possible immune modulation from the vaccine,
305 where the abundance of antibodies produced switched from anti-N following natural
306 infection to anti-S antibodies following vaccination.

307

308 To effectively compare antibody titres (across vaccine groups and assays), a quantitative
309 reference standard and a robust correlation with nAbs is needed for commercial assays to
310 accurately assess the effectiveness of vaccine responses. It will be important for clinical
311 laboratories to identify that vaccine induced antibodies can be detected for each vaccine, and
312 work with public health partners to understand the best use for serological testing. Current
313 guidelines [38, 39] do not recommend clinical serology testing pre or post-vaccination,
314 however these recommendations may change over time with more study. A further
315 understanding of the population-based efficacy and longevity is required to structure
316 recommendations for individualized post-vaccine serology testing in clinical decision
317 making.

318

319 Although sample sizes were low, we observed in the mRNA-1273 group that vaccine-
320 induced antibody responses titres of all three quantitative assays were significantly higher at
321 all time points in participants who recovered from confirmed COVID-19 infection (Table
322 S4). Similar findings have been reported from several other research groups where post-
323 vaccination titres were 10-20 times higher in COVID-19 recovered individuals [40, 41].
324 Furthermore, the responses prior to the second dose of vaccine in COVID-19 recovered
325 participants also exceeded the titres of those from the SARS-CoV-2 naïve participants by 10-
326 fold. This has led to early recommendations by some governments to consider providing
327 only a one-dose primary series in COVID-19 recovered individuals [42].

328

329 For the four participants on immune suppressive treatment who were not previously SARS-
330 CoV-2 infected, a marked difference between nAb and IgG response to vaccination was
331 observed. Although the participants in this group all produced measurable IgG's two weeks
332 after receiving the first vaccine dose, only two gave measurable nAb levels and the remaining
333 two were just above the detection limit. These data underline the importance of assuring
334 immune protection to SARS-CoV-2 in this highly susceptible subpopulation of
335 immunocompromised individuals.

336

337 The principal limitation in our findings is that they only demonstrate the production of
338 vaccine-induced antibodies in response to mRNA COVID-19 vaccines and their
339 quantification. Correlations of specific titre levels to protection or vaccine efficacy cannot be
340 made as the study is not designed or powered for this purpose. As the BNT162b2 and
341 mRNA-1273 vaccines are different products, it is difficult to comment on the difference in
342 median titres seen for the same time points on the same assay (which was observed in general
343 to be lower in the mRNA-1273 group, despite a higher proportion of COVID-19 recovered

344 individuals). This may reflect differing median ages of the two groups or alternatively be
345 reflective of responses to varying vaccine products which is an artifact that could be corrected
346 with an international standard for COVID-19 serology.

347

348 **Conclusions**

349 We have shown that currently available commercial assays for detection of anti-spike IgG
350 binding antibodies were successfully able to detect vaccine induced antibodies in the vast
351 majority of vaccinated participants. In general, anti-spike IgG binding antibody titers
352 increased overtime, while anti-nucleocapsid antibodies declined. There was a marked
353 difference in the proportion of participants eliciting protective nAbs for both vaccines and at
354 all time points after the first dose underlining the difference between a general binding IgG
355 and a functional neutralising response correlating to protection. Just prior to the second dose
356 of vaccination, most samples had detectable neutralising antibodies. However, a significant
357 subpopulation did not produce nAbs which underlines the importance of the continued
358 practice of SARS-CoV-2 infection preventive measures after the first vaccine dose at least for
359 those individuals with no detectable levels of nAbs.

360 **Declarations**

361

362 *Research ethics approval*

363 This study was approved by the Human Research Ethics Board (HREB) at the University of

364 Alberta (reference number Pro00106810).

365

366 *Consent to publication*

367 Not applicable.

368

369 *Conflicts of interest/Competing interests*

370 Sean Taylor is an employee of GenScript USA. He assisted in providing interpretation of the

371 GenScript assay used in this study. He had no role in the design of the study or the formal

372 data analysis, but did provide suggestions for the final draft which were incorporated after

373 review by the other authors. None of the other authors had conflicts to declare with respect to

374 this manuscript.

375

376 *Funding*

377 This work did not receive any specific grant from funding agencies in the public, commercial,

378 or not-for-profit sectors, however testing kits were provided in-kind by all manufactures.

379

380 *Availability of data and material*

381 The datasets used and/or analysed during the current study are available from the

382 corresponding author on reasonable request.

383

384 *Authors' contributions*

385 Jamil N Kanji – Conceptualization, methodology, validation, analysis, data curation, project

386 administration, writing – original draft, writing – review and editing.

387 Ashley Bailey – validation, investigation, data curation, writing – review and editing

388 Jayne Fenton – investigation, data curation, writing – review and editing

389 Sean H Ling – investigation, data curation, project administration, writing – review and

390 editing

391 Rafael Rivera – data curation, formal analysis, writing – review and editing

392 Sabrina Plitt – data curation, formal analysis, project administration, writing – review and

393 editing

394 Wendy I Sligl – data curation, investigation, writing – review and editing, project

395 administration

396 Sean Taylor – resources, writing – review and editing

397 LeeAnn Turnbull – investigation, writing – review and editing

398 Graham Tipples – project administration, writing – review and editing

399 Carmen Charlton – Conceptualization, methodology, validation, resources, writing – original

400 draft, writing – review and editing, supervision, project administration

401

402 *Acknowledgements*

403 We would like to thank Abbott Laboratories, DiaSorin and GenScript for providing us with

404 complimentary serology testing kits.

405

406 *ICMJE Criteria*

407 All authors attest they meet the ICMJE criteria for authorship.

408 **References**

409

- 410 [1] Van Caesele P, Bailey D, Forgie SE, Dingle TC, Kraiden M (2020) SARS-CoV-2
411 (COVID-19) serology: implications for clinical practice, laboratory medicine and public
412 health. *Cmaj* 192 (34):E973-e979
- 413 [2] Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M,
414 Esfandyari S, Mokdad AH, Hotez PJ, Gasser RB (2020) SARS-CoV-2 seroprevalence
415 worldwide: a systematic review and meta-analysis. *Clin Microbiol Infect*
- 416 [3] Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A,
417 Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D,
418 Eller A-K, Grützner J, Boesler C, Rosenbaum C, Kühnle M-C, Luxemburger U, Kemmer-
419 Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi P-Y,
420 Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W,
421 Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Türeci Ö (2020) COVID-19 vaccine
422 BNT162b1 elicits human antibody and TH1 T cell responses. *Nature* 586 (7830):594-599
- 423 [4] Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C,
424 Halkerston R, Hill J, Jenkin D, Stockdale L, Verheul MK, Aley PK, Angus B, Bellamy D,
425 Berrie E, Bibi S, Bittaye M, Carroll MW, Cavell B, Clutterbuck EA, Edwards N, Flaxman A,
426 Fuskova M, Gorringe A, Hallis B, Kerridge S, Lawrie AM, Linder A, Liu X, Madhavan M,
427 Makinson R, Mellors J, Minassian A, Moore M, Mujadidi Y, Plested E, Poulton I, Ramasamy
428 MN, Robinson H, Rollier CS, Song R, Snape MD, Tarrant R, Taylor S, Thomas KM, Voysey
429 M, Watson MEE, Wright D, Douglas AD, Green CM, Hill AVS, Lambe T, Gilbert S, Pollard
430 AJ, Aboagye J, Alderson J, Ali A, Allen E, Allen L, Anslow R, Arancibia-Cárcamo CV,
431 Arbe-Barnes EH, Baker M, Baker P, Baker N, Baleanu I, Barnes E, Bates L, Batten A,
432 Beadon K, Beckley R, Beveridge A, Bewley KR, Bijker EM, Blackwell L, Blundell CL,
433 Bolam E, Boland E, Borthwick N, Boyd A, Brenner T, Brown P, Brown-O'Sullivan C, Brunt
434 E, Burbage J, Buttigieg KR, Byard N, Cabrera Puig I, Camara S, Cao M, Cappuccini F, Carr
435 M, Carroll MW, Chadwick J, Chelysheva I, Cho J-S, Cifuentes L, Clark E, Colin-Jones R,
436 Conlon CP, Coombes NS, Cooper R, Crocker WEM, Cunningham CJ, Damratowski BE,
437 Dattoo MS, Datta C, Davies H, Demissie T, Di Maso C, DiTirro D, Dong T, Donnellan FR,
438 Douglas N, Downing C, Drake J, Drake-Brockman R, Drury RE, Dunachie SJ, Muhanna OE,
439 Elias SC, Elmore MJ, Emary KRW, English MR, Felle S, Feng S, Da Silva CF, Field S,
440 Fisher R, Ford KJ, Fowler J, Francis E, Frater J, Furze J, Galian-Rubio P, Garland H, Godwin
441 K, Gorini G, Gracie L, Gupta G, Hamilton E, Hamlyn J, Hanumunthadu B, Harris SA,
442 Harrison D, Hart TC, Hawkins S, Henry JA, Hodges G, Hodgson SHC, Hou MM, Howe E,
443 Howell N, Huang B, Humphries H, Iveson P, Jackson S, Jackson F, Jauregui S, Jeffery K,
444 Jones E, Jones K, Kailath R, Keen J, Kelly S, Kelly D, Kelly E, Kerr D, Khan L, Khozoe B,
445 Killen A, Kinch J, King TB, King L, Kingham-Page L, Klenerman P, Knight JC, Knott D,
446 Koleva S, Larkworthy CW, Larwood JJP, Lees EA, Lelliott A, Leung S, Li Y, Lias AM,
447 Lipworth S, Liu S, Loew L, Lopez Ramon R, Mallett G, Mansatta K, Marchevsky NG,
448 Marinou S, Marlow E, Marshall JL, Matthews P, McEwan J, McGlashan J, McInroy L,
449 Meddaugh G, Mentzer AJ, Mirtorabi N, Morey E, Morgans R, Morris SJ, Morrison H,
450 Morshead G, Morter R, Moya N, Mukhopadhyay E, Muller J, Munro C, Murphy S, Mweu P,
451 Noé A, Nugent FL, Nuthall E, O'Brien K, O'Connor D, O'Donnell D, Oguti B, Olchawski V,
452 Oliveria C, O'Reilly PJ, Osborne P, Owino N, Parker K, Parracho H, Patrick-Smith M, Peng
453 Y, Penn E, Peralta Alvarez MP, Perring J, Petropoulos C, Pfafferott K, Pipini D, Phillips D,
454 Proud P, Provstgaard-Morys S, Pulido D, Radia K, Rajapaksa D, Ramos Lopez F, Ratcliffe
455 H, Rawlinson T, Pabon ER, Rhead S, Ritchie AJ, Roberts H, Roche S, Rudiansyah I,
456 Salvador S, Sanders H, Sanders K, Satti I, Schmid A, Schofield E, Screatton G, Sedik C,
457 Shaik I, Sharpe HR, Shea A, Silk S, Silva-Reyes L, Skelly DT, Smith CC, Smith DJ, Spencer

- 458 AJ, Stafford E, Szigeti A, Tahiri-Alaoui A, Tanner R, Taylor IJ, Taylor K, te Water Naude R,
459 Themistocleous Y, Themistocleous A, Thomas M, Thomas TM, Thompson A, Tinh L, Tomic
460 A, Tonks S, Towner J, Tran N, Tree JA, Truby A, Turner C, Turner N, Ulaszewska M,
461 Varughese R, Vichos I, Walker L, Wand M, White C, White R, Williams P, Worth AT, the
462 Oxford CVTG (2020) Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a
463 booster dose induces multifunctional antibody responses. *Nature Medicine*
464 [5] Jackson LA, Anderson EJ, Roupheal NG, Roberts PC, Makhene M, Coler RN,
465 McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach
466 B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, 2nd,
467 Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J,
468 Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH (2020) An
469 mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med* 383 (20):1920-
470 1931
471 [6] Centers for Disease Control and Prevention Chickenpox (Varicella): Interpreting
472 laboratory tests, <https://www.cdc.gov/chickenpox/lab-testing/lab-tests.html>. Cited January 1,
473 2021
474 [7] Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser
475 BM, Caradonna TM, Clayton KL, Nitido AD, Murali MR, Alter G, Charles RC, Dighe A,
476 Branda JA, Lennerz JK, Lingwood D, Schmidt AG, Iafate AJ, Balazs AB (2021) COVID-
477 19-neutralizing antibodies predict disease severity and survival. *Cell* 184 (2):476-488.e411
478 [8] Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M-L, Jerome
479 KR, Bloom JD, Greninger AL (2020) Neutralizing antibodies correlate with protection from
480 SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. *Journal of*
481 *Clinical Microbiology*
482 [9] Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, McCune BT,
483 Fox JM, Chen RE, Alsoussi WB (2020) A SARS-CoV-2 infection model in mice
484 demonstrates protection by neutralizing antibodies. *Cell* 182 (3):744-753. e744
485 [10] Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola
486 JP, Liu J, Li Z, Chandrashekar A, Martinez DR, Loos C, Atyeo C, Fischinger S, Burke JS,
487 Slein MD, Chen Y, Zuiani A, Lelis FJN, Travers M, Habibi S, Pessaint L, Van Ry A, Blade
488 K, Brown R, Cook A, Finneyfrock B, Dodson A, Teow E, Velasco J, Zahn R, Wegmann F,
489 Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kirilova M, Kordana N, Lin Z,
490 Maxfield LF, Nampanya F, Nityanandam R, Ventura JD, Wan H, Cai Y, Chen B, Schmidt
491 AG, Wesemann DR, Baric RS, Alter G, Andersen H, Lewis MG, Barouch DH (2020) DNA
492 vaccine protection against SARS-CoV-2 in rhesus macaques. *Science (New York, NY)* 369
493 (6505):806-811
494 [11] Plotkin SA (2010) Correlates of protection induced by vaccination. *Clin Vaccine*
495 *Immunol* 17 (7):1055-1065
496 [12] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector
497 SA, Roupheal N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C,
498 Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J,
499 Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng
500 W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T (2020) Efficacy and Safety of the mRNA-
501 1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*
502 [13] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez
503 Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P,
504 Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S,
505 Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC (2020) Safety and
506 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine* 383
507 (27):2603-2615

- 508 [14] Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, Quandt J,
509 Bidmon N, Ulges A, Baum A, Pascal K, Maurus D, Brachtendorf S, Lörks V, Sikorski J,
510 Koch P, Hilker R, Becker D, Eller A-K, Grützner J, Tonigold M, Boesler C, Rosenbaum C,
511 Heesen L, Kühnle M-C, Poran A, Dong JZ, Luxemburger U, Kemmer-Brück A, Langer D,
512 Bexon M, Bolte S, Palanche T, Schultz A, Baumann S, Mahiny AJ, Boros G, Reinholz J,
513 Szabó GT, Karikó K, Shi P-Y, Fontes-Garfias C, Perez JL, Cutler M, Cooper D, Kyratsous
514 CA, Dormitzer PR, Jansen KU, Türeci Ö (2020) BNT162b2 induces SARS-CoV-2-
515 neutralising antibodies and T cells in humans. medRxiv:2020.2012.2009.20245175
- 516 [15] Roche Roche partners with Moderna to include SARS-CoV-2 antibody test in
517 ongoing COVID-19 vaccine trials, [https://www.roche.com/media/releases/med-cor-2020-12-](https://www.roche.com/media/releases/med-cor-2020-12-09.htm)
518 [09.htm](https://www.roche.com/media/releases/med-cor-2020-12-09.htm). Cited January 17, 2021
- 519 [16] Widge AT, Roupael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M,
520 Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC,
521 Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M,
522 Albert J, Cross K, Edara V-V, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE,
523 Mascola JR, Graham BS, Beigel JH (2020) Durability of Responses after SARS-CoV-2
524 mRNA-1273 Vaccination. *New England Journal of Medicine* 384 (1):80-82
- 525 [17] Government of Alberta COVID-19 vaccine distribution,
526 <https://www.alberta.ca/covid19-vaccine.aspx>. Cited February 4, 2021
- 527 [18] Abbott SARS-CoV-2 Immunoassays,
528 <https://www.corelaboratory.abbott/int/en/offerings/segments/infectious-disease/sars-cov-2>.
529 Cited February 21, 2021
- 530 [19] DiaSorin Liaison(R) SARS-CoV-2 TrimericS IgG Assay,
531 [https://www.diasorin.com/sites/default/files/allegati_prodotti/liaisonr_sars-cov-](https://www.diasorin.com/sites/default/files/allegati_prodotti/liaisonr_sars-cov-2_trimerics_igg_assay_m0870004408.pdf)
532 [2_trimerics_igg_assay_m0870004408.pdf](https://www.diasorin.com/sites/default/files/allegati_prodotti/liaisonr_sars-cov-2_trimerics_igg_assay_m0870004408.pdf). Cited February 21, 2021
- 533 [20] GenScript SARS-CoV-2 surrogate virus neutralization test (sVNT) kit,
534 <https://www.genscript.com/covid-19-detection-svnt.html>. Cited February 21, 2021
- 535 [21] Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, Morrison TE,
536 Huey L, Annen K, DomBourian MG, Knight V (2021) A New SARS CoV-2 Dual Purpose
537 Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response
538 Detection. *J Clin Microbiol*
- 539 [22] Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song
540 G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L,
541 Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee
542 D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG,
543 Burton DR (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection
544 from disease in a small animal model. *Science* 369 (6506):956-963
- 545 [23] Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, Randell P, Pria AD,
546 Lightstone L, Xu X-N, Barclay W, McAdoo SP, Kelleher P, Willicombe M Effect of
547 previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2
548 vaccine. *The Lancet*
- 549 [24] Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T,
550 Noursadeghi M, Boyton RJ, Semper A, Moon JC (2021) Antibody response to first
551 BNT162b2 dose in previously SARS-CoV-2-infected individuals. *Lancet*
- 552 [25] Kempster SL, Almond N, Dimech W, Grangeot-Keros L, Huzly D, Icenogle J, El
553 Mubarak HS, Mulders MN, Nübling CM (2020) WHO international standard for anti-rubella:
554 learning from its application. *Lancet Infect Dis* 20 (1):e17-e19
- 555 [26] Andrew MK, McElhaney JE (2020) Age and frailty in COVID-19 vaccine
556 development. *The Lancet* 396 (10267):1942-1944

- 557 [27] Spradling PR, Xing J, Williams R, Masunu-Faleafaga Y, Dulski T, Mahamud A,
558 Drobeniuc J, Teshale EH (2013) Immunity to hepatitis B virus (HBV) infection two decades
559 after implementation of universal infant HBV vaccination: association of detectable residual
560 antibodies and response to a single HBV challenge dose. *Clin Vaccine Immunol* 20 (4):559-
561 561
- 562 [28] Greub G, Zysset F, Genton B, Spertini F, Frei PC (2001) Absence of anti-hepatitis B
563 surface antibody after vaccination does not necessarily mean absence of immune response.
564 *Med Microbiol Immunol* 189 (3):165-168
- 565 [29] Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo
566 Y, Rofail D, Im J (2021) REGN-COV2, a neutralizing antibody cocktail, in outpatients with
567 Covid-19. *New England Journal of Medicine* 384 (3):238-251
- 568 [30] Perera RAPM, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, To EMW,
569 Yen H-I, Leung K, Cheng SMS, Chan KH, Chan KCK, Li K-C, Saif L, Barrs VR, Wu JT, Sit
570 THC, Poon LLM, Peiris M (2020) Evaluation of a SARS-CoV-2 surrogate virus
571 neutralization test for detection of antibody in human, canine, cat and hamster sera. *Journal of*
572 *Clinical Microbiology*:JCM.02504-02520
- 573 [31] Tan CW, Chia WN, Qin X, Liu P, Chen MIC, Tiu C, Hu Z, Chen VC-W, Young BE,
574 Sia WR, Tan Y-J, Foo R, Yi Y, Lye DC, Anderson DE, Wang L-F (2020) A SARS-CoV-2
575 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike
576 protein-protein interaction. *Nature Biotechnology* 38 (9):1073-1078
- 577 [32] Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ,
578 Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Roupheal N,
579 Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J,
580 Baric RS, de Silva AM (2020) The receptor-binding domain of the viral spike protein is an
581 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Science*
582 *Immunology* 5 (48):eabc8413
- 583 [33] Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E Early rate reductions of
584 SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *The Lancet*
- 585 [34] Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrisnan A, Niesen MJ, O
586 Horo JC, Badley AD, Halamka J, Soundararajan V (2021) FDA-authorized COVID-19
587 vaccines are effective per real-world evidence synthesized across a multi-state health system.
588 *medRxiv:2021.2002.2015.21251623*
- 589 [35] Bruni M, Cecatiello V, Diaz-Basabe A, Lattanzi G, Mileti E, Monzani S, Pirovano L,
590 Rizzelli F, Visintin C, Bonizzi G, Giani M, Lavitrano M, Faravelli S, Forneris F, Caprioli F,
591 Pelicci PG, Natoli G, Pasqualato S, Mapelli M, Facciotti F (2020) Persistence of Anti-SARS-
592 CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers. *J*
593 *Clin Med* 9 (10)
- 594 [36] Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire J,
595 Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatzioannou T, Jenks S,
596 Bieniasz PD (2021) Longitudinal Serological Analysis and Neutralizing Antibody Levels in
597 Coronavirus Disease 2019 Convalescent Patients. *J Infect Dis* 223 (3):389-398
- 598 [37] Mai HK, Trieu NB, Long TH, Thanh HT, Luong ND, Huy LX, Nguyet LA, Man
599 DNH, Anderson DE, Thanh TT, Chau NVV, Thwaites G, Wang LF, Van Tan L, Hung DT
600 (2021) Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild
601 SARS-CoV-2 Infection, Vietnam. *Emerg Infect Dis* 27 (2):663-666
- 602 [38] Government of Canada National Advisory Committee on Immunization (NACI):
603 Recommendations on the use of COVID-19 vaccines, [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html)
604 [health/services/immunization/national-advisory-committee-on-immunization-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html)
605 [naci/recommendations-use-covid-19-vaccines.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html). Cited March 5, 2021

- 606 [39] Centers for Disease Control and Prevention Vaccine Recommendations and
607 Guidelines of the Advisory Committee on Immunization Practices (ACIP): COVID-19 ACIP
608 Vaccine Recommendations, [https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-](https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html)
609 [19.html](https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html). Cited March 5, 2021
- 610 [40] Krammer F, Srivastava K, Simon V (2021) Robust spike antibody responses and
611 increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2
612 mRNA vaccine. medRxiv:2021.2001.2029.21250653
- 613 [41] Saadat S, Tehrani ZR, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM
614 (2021) Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health
615 Care Workers Previously Infected With SARS-CoV-2. JAMA
- 616 [42] British Broadcasting Corporation (BBC) Covid: France says just one jab needed for
617 previously infected, <https://www.bbc.com/news/world-europe-56048444>. Cited February 25,
618 2021
- 619

Table 1. Demographics by type of vaccine administered.

	Total	BNT162b2 group	mRNA-1273 group	p-value ^a
N (%)	225 (100)	177 (78.7)	48 (21.3)	
Median Age (years; IQR)	41 (31-55)	37 (30-48)	84 (75.5-90.5)	<0.001
Gender (%)				0.11
Male	55 (24.4)	39 (22.0)	16 (33.3)	
Female	170 (75.6)	138 (78.0)	32 (66.7)	
Time between dose 1 and dose 2 of vaccine (days)				
Median (IQR)	26 (25-27)	26 (25-28)	25 (24-26)	<0.001
Recovered from COVID-19	22 (9.8)	6 (3.4)	16 (33.3)	<0.001
Of these:				
COVID-19 occurred prior to first vaccine dose (%)	20 (90.9)	4 (66.7)	16 (100)	0.02
Time from COVID-19 diagnosis to first vaccine dose (median, range, days)	45 (30.5-73)	45.5 (36-82)	43 (30.5-73)	0.54
COVID-19 occurred after first vaccine dose (%)	2 (0.9)	2 (33.3)	0	-
Time from first dose to COVID-19 diagnosis (range, days)	20.5 (7-34)	20.5 (7-34)	0	-
Any Co-Morbidity or Immunosuppression (%)	45 (20.0)	9 (5.1)	36 (75.0)	<0.001
Cardiac Disease (%)	27 (12.0)	0	27 (46.3)	<0.001
Diabetes (%)	12 (5.3)	3 (1.7)	9 (18.8)	<0.001
Solid Cancer (%)	5 (2.2)	1 (0.56)	4 (8.3)	0.008
Hematological Cancer (%)	1 (0.44)	1 (0.56)	0	1.00
Asthma (%)	1 (0.44)	1 (0.56)	0	1.00
Renal Disease (%)	5 (2.2)	0	5 (10.4)	<0.001
COPD (%)	8 (3.6)	0	8 (16.7)	<0.001
Dementia (%)	22 (9.8)	0	22 (45.8)	<0.001
Transplant (%)	0	0	0	--
Biologic or immunosuppressant use ^b (%)	5 (2.2)	4 (2.3)	1 (2.1)	1.00
Pregnant (%)	0	0	0	--

Abbreviations: COPD – chronic obstructive pulmonary disease; IQR – interquartile range
^a p-value comparing BNT162b2 and mRNA-1273; calculated by Mann-Whitney test for age, time between vaccine doses and time from COVID-19 diagnosis to first vaccine variables, and chi-square or Fisher’s exact test for remaining variables.

^b Between both groups, five participants were considered immunosuppressed. In the BNT162b2 group, four participants were using biologics (adalimumab, daratumumab/bortezomib, dupilumab, infliximab) for ankylosing spondylitis (n=1), relapsed/refractory multiple myeloma (n=1), atopic dermatitis (n=1), and inflammatory bowel disease (n=1). One participant in the mRNA-1273 group used methotrexate for rheumatoid arthritis. Dupilumab is considered to have a low potential for immunosuppression.

Table 2. Quantitative titers of testing using commercial assays.

Group	Blood sample timepoint	Quantitative titers ^a		
		RBD IgG Titer (AU/mL)	Trimeric S IgG Titer (AU/mL) ^c	nAb Titer (ng/mL)
BNT162b2	Baseline	0 ^b (0-1296.6)	1.85 ^b (1.85-176)	0 ^b (0-1634.7)
	2-weeks	653.3 (300.4-1497.5)	166 (82.6-272)	355.7 (161.6-567.5)
	Pre-2 nd dose	1180 (687.-2135.2)	195 (138-318.5)	628.6 (397-954.6)
mRNA-1273	2-weeks	157.7 (22.6-4083.5)	27.6 (2.1-235.5)	85.6 (0-462.4)
	Pre-2 nd dose	557.3 (167.9-8210.6)	112 (34.5-764)	381.1 (11.9-8802.8)
P-values				
BNT162b2 ^d	Baseline vs. 2 weeks	<0.0001	<0.0001	<0.0001
	2 weeks vs. Pre-2 nd dose	<0.0001	<0.05	<0.0001
mRNA-1273	2 weeks vs Pre-2 nd dose	0.06	<0.01	<0.05

^aExpressed as median value (IQR), except for BNT162b2 baseline samples.

^bExpressed as median value (range) due to low numbers of positive samples.

^cAccording to product insert, titers <13 AU/mL (negative) and ≥13 AU/mL (positive).

^dAll p-values comparing baseline to pre-2nd dose for the BNT162b2 vaccine <0.0001, except for Nucleocapsid IgG where p-value=1.0; NS= Not Significant.




Figure 1. Positivity rates of each assay tested for each group at different time points. Positivity rates are presented in (%).


^aBaseline versus 2 weeks comparison (BNT162b2): p=NS (Nucleocapsid IgG); p<0.0001 (RBD IgG, Trimeric S IgG, and nAb assays).

^b2-week versus pre-2nd dose comparison (BNT162b2): p=NS for all assays.


^cAll p-values comparing baseline to pre-2nd dose (BNT162b2) vaccine were <0.0001, except for nucleocapsid IgG (p=1.0).

^d2-weeks versus pre-2nd dose comparison (mRNA-1273): p=NS (Nucleocapsid IgG); p<0.01 (RBD IgG); p<0.05 (Trimeric S IgG and nAb assays).


a




b



c



d



e




Figure 2. Quantitative testing results from time of first vaccine dose for each vaccine group using the nAb assay (panels a and b); Trimeric S IgG assay (panel c); and RBD IgG assay (panels d and e). Panel (b) presents panel (a) results with y-axis limited to maximum titer of 6000 ng/mL. Panel (e) presents panel (d) results with a shortened y-axis (max titer 5000 AU/mL).